Review of Qualification Data for Biomarkers of Nephrotoxicity Submitted by the Predictive Safety Testing Consortium
Melanie Blank(United States Food and Drug Administration), Shen Xiao(Research Triangle Park Foundation), Albert De Felice, David Jacobson‐Kram(United States Food and Drug Administration), Federico Goodsaid, Elizabeth A. Hausner(United States Food and Drug Administration), Aliza Thompson(United States Food and Drug Administration), William Taylor(United States Food and Drug Administration), Douglas C. Throckmorton(United States Food and Drug Administration), Patricia Harlow(United States Food and Drug Administration)
Unknown
January 1, 2009
Cited by 19
Related Papers
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements
|Nature Biotechnology|2006|2.2k
Evaluation of DNA microarray results with quantitative gene expression platforms
|Nature Biotechnology|2006|619
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
|Clinical Pharmacology & Therapeutics|2007|582
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
|Nature Biotechnology|2010|406